Abstract library

96 results for "Pando".
#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Soledad Cameselle-Garcia
#2180 BRAF-V600E Driven Mutations in Grade 3 Neuroendocrine Carcinomas of Colon Origin: Results from Genomic/Epigenomic Profilings and Patient-Derived Mouse Model
Introduction: NECs of colon origin are orphan and highly aggressive neoplasms with limited molecular knowledge.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jaume Capdevila
#2749 Impact of Next-Generation Sequencing Analyses on Treatment Management of Patients with Advanced Neuroendocrine Neoplasms
Introduction: Molecular genomic analyses are widely used in oncology but experience in advanced neuroendocrine neoplasms (NENs) is still limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Alejandro Garcia-Alvarez
Keywords: NGS, BRAF, RET
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker
Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD INES DE TORRES
#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#193 Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) are rare fatal cancers. Many patients develop metastatis before diagnosis. There is no available curative treatment for patients with metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Associate Profes Valeria Giandomenico
Authors: Cui T, Hurtig M, Li S C, Veronesi G, ...
#198 Novel Insights in Octreotide Effects on Human Neuroendocrine Cell Line CNDT2.5
Introduction: Octreotide, the first synthetic somatostatin analog available for clinical use, efficiently binds somatostatin receptors (SSRs) 2 and 5 and may transduce its effects by using SSRs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Cui T, Martijn C, Öberg K, ...
#200 Genome-Wide MicroRNA Expression in Small Intestine Neuroendocrine Tumors (“Midgut carcinoids”): Upregulation of miRNA-182, miRNA-183 and Downregulation of miRNA-215
Introduction: MicroRNAs (miRs) may regulate cell proliferation, differentiation, apoptosis and function as tumor suppressors or oncogenes. MiR expression is not characterized in neuroendocrine midgut carcinoids.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: PhD student Su-Chen Li
#355 MicroRNA Signatures as Novel Biomarkers in Small Intestine Neuroendocrine Tumors
Introduction: Small intestine (SI) neuroendocrine tumors (NET) arise from serotonin-producing intraepithelial cells in the SI referred to as enterochromafin cells. The detection of SI-NETs is often concomitant with the appearance of hepatic metastasis thus most patients with SI-NET have metastases at initial presentation. MicroRNAs (miRs) are post-transcriptional key regulators in tumorigenesis which regulate expression of other genes. Little evidence of miR expression or deregulation in SI-NETs has been reported.
Conference:
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Ahmed E, Martijn C, Lloyd R, ...